ClinicalTrials.gg
RecruitingNCT07026591EPICOUpdated Oct 6, 2026

Epilepsy and Driving

An observational study in Epilepsy, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild — 7 open to participants now, 7 under way, none of them phase 3. Epilepsy · Fondation Ophtalmologique Adolphe de Rothschild.

Started
2025
with 1 other
Observational
7 of 10
5 open now
Registered
8th of 10
by date

Among the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild, this one is one of 2 that started in 2025, is one of 7 observational ones, and was the 8th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

7 of the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild, or all of them as a file.
02

Study summary

Epilepsy can lead to cognitive impairments, particularly in attention, which may affect daily activities such as driving. Driving plays a key role in maintaining autonomy and is essential for the social and professional integration of people with epilepsy. Therefore, assessing fitness to drive is a major issue for individuals with epilepsy.

French legislation governing driving for people with epilepsy clearly outlines the periods during which a person is not permitted to drive. However, the means or methods for evaluating driving fitness in these individuals are not well defined. Currently, assessment is based more on a medical consultation than on a comprehensive evaluation of driving ability.

Using a driving simulator in combination with an EEG could be a valuable approach to better assess the impact of epilepsy-related cognitive impairments on driving performance.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Epileptic patients and healthy volunteers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 65 years
  • Holder of a category B driving license
  • Active driver: drives at least once a month
  • No medical condition contraindicating driving, except for epilepsy
  • Provides explicit consent to participate in the study
  • Affiliated with or a beneficiary of a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Subject to legal protection (guardianship and curatorship are accepted for individuals with epilepsy, as this population represents a significant proportion of our institution's patients)
  • Pregnant or breastfeeding women
  • Known cybersickness (virtual reality or simulator sickness)
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • epilectic patients

    Individuals with epilepsy who drive at least once a month

  • healthy volunteers

    healthy volunteers driving at leat once a month, matched to epileptic patients on age (+-/ 5 years), sex and driving experience (+/-3 years)

06

What researchers measure

Primary outcomes

  1. Speed

    Mean speed during the simulated driving task

    Time frame: Day 0

  2. Phasic alertness

    Phasic alertness on neuropsychological test (TAP)

    Time frame: Day 0

  3. Lane position

    Mean lane position during the simulated driving task

    Time frame: Day 0

  4. Braking time

    Mean braking time during the simulated driving task

    Time frame: Day 0

  5. Information processing time

    Mean information processing time during the simulated driving task

    Time frame: Day 0

  6. Sustained attention

    Sustained attention on neuropsychological test (TAP)

    Time frame: Day 0

  7. Divided attention

    Divided attention on neuropsychological test (TAP)

    Time frame: Day 0

  8. Visual scanning

    Visual scanning on neuropsychological test (TAP)

    Time frame: Day 0

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 18, 2025
StartActual
Nov 6, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07026591
Responsible party
Sponsor
First posted
Jun 18, 2025
Start date
Nov 6, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Amelie Yavchitz
Contact
ayavchitz@for.paris
+33 1 48 03 64 54

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion